Abstract
Obesity is a common and increasing problem affecting the developed world. Chemotherapy pharmacokinetics in the context of obesity demonstrate prolonged elimination time for several agents, but there is no consensus regarding optimal dosing schemes. Retrospective studies suggest differences in toxicity for obese adult patients but these data may be greatly impacted by chemotherapy dose adjustments. Outcome data from several studies have suggested that obese adult patients suffer poorer disease-free survival and overall survival, although this is not a uniform conclusion in all studies. Prospective studies of chemotherapy pharmacokinetics are needed to address the issue of optimal chemotherapy dosing in the obese population.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
